Post-Traumatic Stress Disorder Therapeutics Global Market Report 2024

The post-traumatic stress disorder therapeutics market size has grown strongly in recent years. It will grow from $1.09 billion in 2023 to $1.15 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth observed in the historical period can be attributed to factors such as heightened awareness, increased incidence of trauma, government initiatives, advancements in diagnostic tools, efforts to reduce stigma, and the implementation of psychological support programs with a specific focus on veteran healthcare.

The post-traumatic stress disorder therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.35 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. The anticipated growth in the forecast period can be attributed to the expansion of access to mental health services, the implementation of government mental health policies, advancements in biological and neurological research, the consideration of PTSD in non-military populations, and the development of crisis response planning. Key trends expected in the forecast period encompass the integration of digital therapeutics, progress in pharmacological treatments, the exploration of neurostimulation and brain stimulation techniques, the emergence of psychedelic-assisted therapy, and collaborative research initiatives.

The anticipated increase in the prevalence of post-traumatic stress disorder (PTSD) cases worldwide is expected to drive the growth of the market for therapeutics addressing PTSD. PTSD is a condition that develops in individuals who have experienced a frightening, shocking, or dangerous event. Treatment options for post-traumatic stress disorder, such as psychotherapy and medication, play a crucial role in helping individuals regain control over their lives. For instance, the United States Department of Veterans Affairs reported that nearly 8 million Americans were grappling with PTSD in 2021, highlighting the surge in PTSD cases as a key driver for the growth of the post-traumatic stress disorder therapeutics market.

The increasing incidence of mental health issues is projected to contribute to the expansion of the post-traumatic stress disorder (PTSD) therapeutic market. Mental health issues encompass a broad spectrum of conditions affecting an individual's thinking, perceptions, feelings, and behaviors. Therapeutics for PTSD address mental health issues through a combination of psychotherapy, medication, and other interventions. According to a 2022 survey by the House of Commons Library, 18.0% of children aged 7-16 were identified with a probable mental disorder in 2022, with an expected rise to 25.7% in 2022. Consequently, the growing prevalence of mental health issues is a key factor driving the growth of the post-traumatic stress disorder (PTSD) therapeutic market.

Strategic collaborations, funding, and investments have emerged as a prominent trend in the post-traumatic stress disorder therapeutics market. Major companies in the market are forming strategic collaborations and investing in various initiatives to fortify their positions. In January 2022, Professor Dan Lubman AM, Dr. Shalini Arunogiri, and Dr. Paul Liknaitzky of Monash University secured over $1.9 million for a study on the effectiveness of MDMA-assisted psychological treatment for alcohol use disorder (AUD) and PTSD. This initiative, part of the Medical Research Future Fund (MRFF), is one of seven clinical studies aiming to evaluate the potential of combination medicines for treating severe mental disorders.

Leading organizations in the post-traumatic stress disorder therapeutics market are actively establishing innovative research centers, including psychedelics research centers, to explore psychedelic compounds and gain a competitive edge. Psychedelics research centers focus on studying the therapeutic applications of psychedelic compounds and developing new treatments for mental health disorders. For example, in January 2021, the Mount Sinai Health System launched the Center for Psychedelic Psychotherapy and Trauma Research, dedicated to researching psilocybin, MDMA, and other psychedelic substances. The center aims to conduct clinical trials necessary for the widespread use of psychedelic-assisted psychotherapies.

In June 2023, Stella Center, a U.S.-based provider of PTSD treatment, acquired the U.S. assets of Field Trip Health for an undisclosed amount. This acquisition is expected to expand Stella's range of advanced treatments, including Field Trip Health's outcomes data, research, technology stack, clinics, and leadership. Field Trip Health, a Canada-based provider of psychedelic-assisted therapies for mental health conditions, including PTSD, is the focus of this strategic move.

Major companies operating in the post-traumatic stress disorder therapeutics market report are Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Bionomics Limited, Apotex Inc., Otsuka Pharmaceutical Co Ltd., Eli Lilly and Company, Behavioral Health Network Inc., AstraZeneca plc, Prometheon Pharma LLC, Tonix Pharmaceuticals Holding Corp., Freespira Inc., MicroTransponder Inc., Addex Therapeutics Ltd., Stella Center, Neurovation Labs Inc., Equip Global Pte Ltd., Compass Pathways plc, Boehringer Ingelheim International GmbH, Halucenex Life Sciences Inc., Bionorica SE, MAPS Europe BV, Hoffmann-La Roche Ltd., Praxis Precision Medicines Inc., H Lundbeck A/S, Johnson & Johnson, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Amgen Inc., Biogen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Merck KGaA, Sun Pharmaceuticals Industries Limited, Strategic Behavioral Health, Jazz Pharmaceuticals plc.

North America was the largest region in the post-traumatic stress disorder therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-traumatic stress disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the post-traumatic stress disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key drugs utilized in post-traumatic stress disorder therapeutics encompass antidepressants, anti-anxiety medications, antihypertensive drugs, monoamine oxidase inhibitors (MAOIs), antipsychotics or second-generation antipsychotics (SGAs), beta-blockers, and others (including benzodiazepines and others). Antidepressants, a specific class of drugs, are employed to manage addictions and address conditions such as major depressive disorder, anxiety disorders, and chronic pain. The therapeutic interventions are administered across diverse age groups, including pediatric, geriatric, and adult populations, and are utilized by various end-users, including mental health centers, hospitals, outpatient clinics, and other healthcare facilities.

The post-traumatic stress disorder therapeutics market research report is one of a series of new reports that provides post-traumatic stress disorder therapeutics market statistics, including post-traumatic stress disorder therapeutics industry global market size, regional shares, competitors with a post-traumatic stress disorder therapeutics market share, detailed sulfuric acid market segments, market trends and opportunities, and any further data you may need to thrive in the post-traumatic stress disorder therapeutics industry. This sulfuric acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.